[Pharmacokinetic and pharmacodynamic features of hypertensive drugs in treatment of patients with arterial hypertension associated with liver disease].
Being based on pharmacokinetic and pharmacodynamic property of inhibitor ACE and -adrenoblokers to optimise treatment of patients arterial hypertension (AH), a liver proceeding against chronic diseases. In research it is included 360 patients with AH 2 degree in a combination with steatosis and the cirrhosis of liver of an alcoholic etiology of a class A by Chald-Pugh. In control group patients with stomach ulcer are included in stages of remission with normal function of a liver. For the purpose of diagnostics AH and an efficiency estimation hypotensive preparations the patient it is spent systolic arterial pressure. For a pharmacokinetics estimation definition of concentration of preparations in whey of blood sick of a method of a highly effective liquid chromatography was spent. At patients AH with the normal and broken function of a liver after reception lizinoprili and atonololi it is noted distinctions in pharmacokinetic parametres. The broken function of a liver at patients AH against the cirrhosis lover is at the bottom of changes pharmacokinetic parametres metoprololi and enalaprili.